T2D

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

Wednesday, September 15, 2021 - 6:35am

SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).

Key Points: 
  • SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).
  • Hua Medicine will rely on Sinopharm's nation-wide drug distribution network to carry out in-depth cooperation in supply chain management.
  • "We are very glad to witness the strategic cooperation between Sinopharm and Hua Medicine, opening a new chapter on our cooperation.
  • In recent years, Sinopharm continue to innovate and build up the new ecosystem of the smart pharmaceutical and supply chain, improving the efficiency of supply chain.

Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results

Thursday, August 12, 2021 - 1:05pm

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today updated a key clinical development milestone and reported its second-quarter 2021 financial results.

Key Points: 
  • SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today updated a key clinical development milestone and reported its second-quarter 2021 financial results.
  • We are just a few months away from important clinical data readouts for both our MET409 and MET642 programs, said Preston Klassen, M.D., MHS, CEO, Metacrine.
  • On July 9, 2021, Metacrine presented new preclinical data in IBD at the European Crohns and Colitis Organisation (ECCO) 2021 Virtual Congress.
  • The increase was primarily driven by higher clinical development costs related to the advancement of the Companys MET409 and MET642 programs.

Glyscend Therapeutics Announces Preclinical Data at ADA 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

Wednesday, August 4, 2021 - 8:46pm

Glyscend Inc presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, June 25-29, 2021, from a study of its proprietary oral polymer duodenal exclusion therapy.

Key Points: 
  • Glyscend Inc presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, June 25-29, 2021, from a study of its proprietary oral polymer duodenal exclusion therapy.
  • The study evaluated the metabolic effects of its therapeutic (GLY-POL) in a non-obese T2D Goto-Kakizaki (GK) rat model, compared to control.
  • Similar reduction in PPG iAUC was evident during mixed meal tolerance testing (iAUC > 55%), suggesting that oral, polymer-based duodenal exclusion therapy is a viable method of improving glucose homeostasis.
  • Glyscend aims to replicate the beneficial effects of bariatric surgery via the duodenal exclusion mechanism, without the need for surgery.

Fractyl Announces Closing of $100 Million Series F Financing to Expand Clinical Development Programs in Type 2 Diabetes

Wednesday, June 16, 2021 - 11:00am

Fractyl Health , a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the closing of a $100 million Series F financing.

Key Points: 
  • Fractyl Health , a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the closing of a $100 million Series F financing.
  • This financing will enable the expansion and acceleration of our clinical development efforts with the goal of reducing insulin dependence for patients with type 2 diabetes on a global scale.
  • Fractyl recently obtained FDA Breakthrough Device Designation for Revita DMR in patients with type 2 diabetes (T2D) who are currently treated with insulin.
  • We are enthusiastically committed to supporting Fractyl as it drives forward its development and commercial programs to realize the full range of Revitas potential in type 2 diabetes.

Diabetes Reversal Leader Virta Health Appoints Public Policy Veteran Cybele Bjorklund to Lead Government Efforts

Wednesday, June 9, 2021 - 2:10pm

Virta Health , the type 2 diabetes reversal leader, today announced several additions to its executive team, including the appointment of Cybele Bjorklund as Senior Vice President (SVP) of Policy and Government Affairs.

Key Points: 
  • Virta Health , the type 2 diabetes reversal leader, today announced several additions to its executive team, including the appointment of Cybele Bjorklund as Senior Vice President (SVP) of Policy and Government Affairs.
  • (Photo: Business Wire)
    A Capitol Hill veteran, Bjorklund joins Virta to bring type 2 diabetes (T2D) reversal to the near 50% of Americans who receive healthcare coverage through a government program.
  • Of the $327 billion spent annually on diabetes, two-thirds is provided by government insurance, according to the American Diabetes Association .
  • Rarely in healthcare do we see something this impactful, said Cybele Bjorklund, SVP of Policy and Government Affairs at Virta Health.

Fractyl Announces FDA Breakthrough Device Designation for Revita® DMR in Insulin-Treated Type 2 Diabetes

Tuesday, April 27, 2021 - 12:00pm

b'Fractyl Laboratories Inc. ( Fractyl ), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Revita\xc2\xae DMR in patients with insulin-treated type 2 diabetes (T2D).

Key Points: 
  • b'Fractyl Laboratories Inc. ( Fractyl ), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Revita\xc2\xae DMR in patients with insulin-treated type 2 diabetes (T2D).
  • We know that treatment alternatives to current drug therapy are desperately needed to address the type 2 diabetes epidemic,\xe2\x80\x9d said Juan Carlos Lopez-Talavera, M.D., Ph.D., Chief Medical Officer of Fractyl.
  • Revita DMR has received FDA Breakthrough Device Designation and a European Union CE mark.
  • Fractyl\xe2\x80\x99s lead program is Revita DMR, an outpatient endoscopic procedural therapy designed to treat insulin resistance in type 2 diabetes.

Virta Health’s Reversal Treatment Prevents Progression to Type 2 Diabetes in 97% of Prediabetes Patients, New Research Shows

Tuesday, March 2, 2021 - 5:39pm

Today Virta Health , the type 2 diabetes reversal leader, announced the publication of new peer-reviewed research in Nutrients .

Key Points: 
  • Today Virta Health , the type 2 diabetes reversal leader, announced the publication of new peer-reviewed research in Nutrients .
  • In this publication, Virta reports best-in-class outcomes in diabetes prevention, with only 3% of trial participants progressing to type 2 diabetes (T2D) and over half achieving prediabetes reversal during the first two years.
  • Virta now offers T2D reversal, prediabetes reversal, and obesity treatment to members of its enterprise, health plan, and government customers.
  • For more information on Virtas research and treatment to reverse type 2 diabetes and prediabetes, please visit www.virtahealth.com .

Insights on Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2029 - ResearchAndMarkets.com

Tuesday, November 17, 2020 - 10:27am

The "Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • In particular, the publisher expects US market will contribute the most to the antidiabetic market's growth, contributing sales in $28B sales in 2019 (58% of the global antidiabetic market) and $57B in 2029 (62% of the global antidiabetic market).
  • Other major drivers for the T2D market are the increasing prevalence of obesity and the increasing prevalence of cardiovascular and kidney disease .
  • Develop business strategies by understanding the trends shaping and driving the global angina pectoris therapeutics market.

vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study

Wednesday, November 4, 2020 - 12:30pm

The data demonstrate that the patients enrolled in Elevage (n=43) have similar baseline characteristics to those in the STEADFAST A-study type 2 diabetes (T2D) subgroup (NCT02080364) (n=47).

Key Points: 
  • The data demonstrate that the patients enrolled in Elevage (n=43) have similar baseline characteristics to those in the STEADFAST A-study type 2 diabetes (T2D) subgroup (NCT02080364) (n=47).
  • The goal of the Elevage study is to confirm the results of these retrospective analyses in a 6-month Phase 2 study prior to initiating a Phase 3 study.
  • The Elevage data are being presented today at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference - Digital Event, which is being held virtually November 4-7, 2020.
  • The Elevage study for azeliragon in this patient population is designed as sequential Phase 2 and 3 trials operationally conducted under one protocol.

Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients

Tuesday, September 15, 2020 - 1:25pm

Forty-one health care providers, including 22 endocrinologists and 19 primary care physicians, nurse practitioners, physician assistants and certified diabetes educators were surveyed.

Key Points: 
  • Forty-one health care providers, including 22 endocrinologists and 19 primary care physicians, nurse practitioners, physician assistants and certified diabetes educators were surveyed.
  • There was strong support among these health care providers for use of oral insulin with T2D patients early in the treatment process through a primary care physician before the need for injectable insulin and before the patient is moved to an endocrinologist for diabetes care.
  • Overall, health care providers stated they would "strongly recommend oral insulin" for:
    T2D patients currently on oral medication;
    T2D patients who are candidates for insulin; and
    T2D patients who are candidates for basal insulin.
  • Oramed's Chief Executive Officer, Nadav Kidron, commented, "This latest market survey further confirms the value of our oral insulin capsule.